PhD Scientific Days 2019

Poster presentations: Oncology

Attributes of extreme long term survivors - identification of high stage cancer patients with extended overall survival.

Előadó neve

Dr. Bartha, Aron

Előadó munkahelye

2nd Department of Pediatrics, Semmelweis University

Előadó telefonszáma

+36709461583

Előadó e-mail címe

bartha.aron@med.semmelweis-univ.hu

Az előadás címe

Attributes of extreme long term survivors - identification of high stage cancer patients with extended overall survival.

Szerző(k) neve és munkahelye

Áron Bartha(1), Balázs Győrffy(1,2)
1. Semmelweis University, 2nd Department of Pediatrics, H-1094, Budapest, Hungary
2. MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Magyar tudósok körútja 2., H-1117, Budapest, Hungary

Bemutatás módja

Poszter

Szekció

Poster presentations: Oncology

Language of the presentation

English

Témacsoport

oncology (experimental and clinical)

Összefoglaló szövege

Background: Each cancer types, shows notable differences between the overall survival rates. Patients with high stage tumor disease have significantly worse prognosis compared to lower stage patients. However, even some of these patients experience exceptional long survival rates.

Aim: Our aim was to identify those cohorts of patients where survival rates surpass majority in a positive manner.

Methods: We examined seven tumor types: colorectal carcinoma (mCRC), breast cancer(mBC), melanoma(mML), lung cancer(mLC), gastric cancer (mGC), pancreas carcinoma(mPC) and ovarian cancer(mOC). Only metastatic or high grade patients were included. Usingthe National Comprehensive Cancer Network (NCCN)database, we obtained those publications which were phase II or III clinical trials with available survival plots (Kaplan-Meier plots). The webplotdigitizer web-tool (https://apps.automeris.io/wpd/) was employed to re-digitalize the survival plots. We calculated the median survival time of the 10th percent of the proportion of longest living patients with simultaneously including censoring events in the analysis. Trials for the same tumor type were processed separately and the results were averaged.

Results: We analyzed 53 eligible clinical trials from NCCN data, including mLC: n= 9, mBC: n= 8, mCRC: n=8, mML: n=10, mGC: n= 5, mOC: n=5, and mPC: n= 8. The median survival at the 10th percentile of the longest living patients for the selected tumors: mlc: 23,21 months,(14,83-35,4 months), mbc: 39,81 months(30,08-49 months), mcrc: 54.5 months(31,5-70,8 months), mml: 76,1 months(51,96-165,56 months), mgc: 22.82 months(17,39-37,52months), moc: 38.67 months(26,65-151,9 months), mpc: 17.37 months(11,72-30,09 months).

Conclusion:In our study, using previous clinical trials we re-computed the survival percentiles and defined the time necessary to achieve an exceptional survivor status in different kinds of solid tumors.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4084

Presentation file URL

//docs.kmcongress.com/phd2019/eposter_5965.jpeg

Authors (legacy)

Áron Bartha(1), Balázs Győrffy(1,2)
1. Semmelweis University, 2nd Department of Pediatrics, H-1094, Budapest, Hungary
2. MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Hungarian Academy of Sciences, Magyar tudósok körútja 2., H-1117, Budapest, Hungary

Data of the presenter

Doctoral School: Pathological Sciences
Program: Oncology
Supervisor: Balázs Győrffy
E-mail address: bartha.aron@med.semmelweis-univ.hu